Study To Evaluate Treating Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis Patients
NCT01089686 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2
Last updated 2012-03-07
Summary
This is a single center, multispecialty, randomized double blind placebo control feasibility clinical trial. The purpose is to evaluate the safety, feasibility and efficacy of percutaneous transluminal angioplasty in treating extracranial venous obstructive lesions, and its influence on the clinical outcomes of Multiple Sclerosis (MS) patients that have been found to have chronic cerebrospinal venous insufficiency (CCSVI).
Conditions
Interventions
- PROCEDURE
-
Venoplasty
Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Venoplasty is performed by inserting an additional catheter with a balloon at the tip. The balloon will be inflated to open the vessel. Once dilation of the vessel is confirmed, the venous sheath will be removed and manual compression applied to the groin access.
- PROCEDURE
-
Sham procedure (non-treatment)
Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Since the patient has been randomized to the non-treatment arm of the trial, the procedure will end without venoplasty. After completion of the diagnostic venogram, the venous sheath will be removed and manual compression applied to the groin access.
Sponsors & Collaborators
-
Center for Vascular Awareness, Albany, New York
collaborator OTHER -
Manish Mehta, MD
lead OTHER
Principal Investigators
-
Manish Mehta, MD, MPH · The Vascular Group, PLLC
Study Design
- Allocation
- RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-08-31
- Primary Completion
- 2012-10-31
- Completion
- 2012-10-31
Countries
- United States
Study Locations
More Related Trials
-
Prospective Randomized Endovascular Therapy in Multiple Sclerosis - PREMiSE
NCT01450072 ·Status: COMPLETED ·Phase: NA
-
Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis
NCT03822858 ·Status: AVAILABLE
-
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
NCT04380220 ·Status: UNKNOWN
-
Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis
NCT02369926 ·Status: UNKNOWN ·Phase: PHASE2
-
Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS
NCT00813969 ·Status: COMPLETED ·Phase: PHASE1
-
Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis
NCT02326935 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis
NCT05064436 ·Status: TERMINATED ·Phase: PHASE1
-
Analysis of Neurodegenerative Process Within Visual Ways In Multiple Sclerosis
NCT03656055 ·Status: COMPLETED
-
Standardized Ambulatory Neurorehabilitation Program for Patients With Multiple Sclerosis
NCT02440516 ·Status: COMPLETED ·Phase: NA
-
Measuring Active Microglia in Progressive Multiple Sclerosis
NCT02207075 ·Status: COMPLETED
-
Cerebrovascular Changes in Multiple Sclerosis Patients
NCT03709290 ·Status: UNKNOWN
-
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for MS
NCT05003388 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS
NCT02587715 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis
NCT06592703 ·Status: RECRUITING ·Phase: PHASE1
-
Acute Intermittent Hypoxia in Persons With Multiple Sclerosis
NCT04280484 ·Status: COMPLETED ·Phase: NA
-
Epidural Stimulation in Multiple Sclerosis
NCT06019611 ·Status: COMPLETED ·Phase: NA
-
Lipoic Acid for Progressive Multiple Sclerosis (MS)
NCT03161028 ·Status: COMPLETED ·Phase: PHASE2
-
Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis
NCT02034188 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Mechanisms of Disease Severity in Multiple Sclerosis: an Integrative Multimodal Study
NCT03369106 ·Status: ACTIVE_NOT_RECRUITING
-
Validation of Multimodal Evoked Potentials (mmEP) for Predicting Disease Progression in Multiple Sclerosis
NCT03632473 ·Status: COMPLETED
-
Cortical Inhibition in Patients With Multiple Sclerosis
NCT07128160 ·Status: NOT_YET_RECRUITING
-
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
NCT05663853 ·Status: COMPLETED
-
A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting
NCT03589105 ·Status: COMPLETED ·Phase: PHASE4
-
Neural Stem Cell Transplantation in Multiple Sclerosis Patients
NCT03269071 ·Status: COMPLETED ·Phase: PHASE1
-
Use of a Smartphone Application to Predict the Prognosis in Patients With Newly Diagnosed Multiple Sclerosis.
NCT04595799 ·Status: ACTIVE_NOT_RECRUITING